On May 13, 2022, Green Valley Pharmaceuticals officially announced that due to the multiple impacts of the Corona Virus Disease 2019(COVID-19) and the lack of financing, the company terminated the international multi-center phase III clinical study of GV-971 ahead of schedule. Although the ...